October 13, 2016
Adocia Announces Third Quarter 2016 Financial Results
Adocia a clinical stage biopharmaceutical company announced today third quarter revenue and net cash position ending September 30,2016.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Eli Lilly
October 9, 2016
New Data on the Combination of Lilly’s ALIMTA and Merck’s KEYTRUDA
Important clinical study results from one of Eli Lilly and Company’s ongoing immuno-oncology collaborations with Merck (known as MSD outside…
March 15, 2016
Lilly includes a single primary endpoint of cognition (ADAS-Cog14) to EXPEDITION3 trial
Lilly includes a single primary endpoint of cognition (ADAS-Cog14) to EXPEDITION3 trial
March 7, 2016
Lilly and Novartis reveal separate studies on plaque psoriasis
Good news for patients with moderate-to-severe plaque psoriasis. In only two days two big pharmaceutical companies have issued press releases about…
December 17, 2015
Lilly’s and Boehringer Ingelheim’s insuline injection gets FDA’s nod
Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) were granted approval by the U.S. Food and Drug Administration (FDA) for Basaglar (insulin glargine injection) 100 units/mL.
December 16, 2015
Lilly welcomes new board member
Eli Lilly and Company has elected Juan R. Luciano as a new member of its board, effective February 1, 2016.
December 4, 2015
Lilly quits developing basal insulin peglispro
Eli Lilly and Company will cease development of basal insulin peglispro (BIL), a potential treatment for type 1 and type 2 diabetes, in order to focus research and development efforts on other assets in its portfolio and pipeline.
November 24, 2015
Lilly’s lung cancer drug in combo with gemcitabine and cisplatin gets FDA’s OK
Eli Lilly has gotten the U.S. Food and Drug Administration (FDA) approval for cancer drug Portrazza, which comes in a form of injection for intravenous use, 800 mg/50 mL, in combination with gemcitabine and cisplatin.
November 19, 2015
Lilly and Merck move on with oncology clinical trial of and Keytruda
Eli Lilly and Merck are moving on with an existing oncology clinical trial collaboration to evaluate the safety and efficacy of the combination of Lilly’s Almita (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
November 9, 2015
Lilly’s ixekizumab shows improvements in signs and symptoms of their disease when compared to placebo
Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…